Skip to main content
. Author manuscript; available in PMC: 2009 Sep 4.
Published in final edited form as: J Biopharm Stat. 2008;18(6):1063–1083. doi: 10.1080/10543400802369004

Table 2. Pharmacokinetics Parameter Estimates for KETO and MDZ.

Parameters Methods
Model 2* Model 1**
Estimate 90% CI*** Estimate 90% CI***
KETO:
V1I 20.6 (16.0, 24.6) 21.3 (17.5, 26.0)
V2I 24.4 (16.3, 37.0) 33.8 (17.9, 44.6)
V maxI 23.1 (20.1, 26.4) 22.2 (18.0, 26.9)
CL12I 3.22 (2.53, 4.04) 2.10 (1.10, 3.78)
kaI,TM 0.42 (0.37, 0.48) 0.45 (0.33, 0.65)
kaI,TF 0.61 (0.42, 1.10) 0.72 (0.53, 1.07)
kaI,SPF 2.03 (1.55, 2.35) 1.79 (0.95, 1.92)
kaI,SLM 0.70 (0.60, 0.98) 0.76 (0.58, 1.10)
kaI,SLF 2.72 (2.33, 3.14) 2.23 (1.65, 3.32)
ωV1I 0.22 (0.10, 0.42) 0.13 (0.06, 0.26)
ωV2I 0.44 (0.23, 0.81) 0.66 (0.33, 1.14)
ωVmaxI 0.17 (0.10, 0.29) 0.15 (0.08, 0.26)
ωCL12I 0.54 (0.35, 1.34) 0.77 (0.40, 1.37)
ωkaI 0.34 (0.17, 0.69) 0.40 (0.18, 0.71)
σV1I 0.067 (0.016, 0.13) N/A
σV2I 0.316 (0.24, 0.40) N/A
σV maxI 0.08 (0.04, 0.13) N/A
σkaI 0.92 (0.86, 0.98) N/A
σCL12I 0.32 (0.24, 0.40) N/A
σI0 0.20 (0.06, 0.30) N/A
MDZ :
V1S 78.8 (48.1, 120.7) 70.05 (51.1, 112.1)
V2S 53.3 (31.2, 89.7) 49.08 (29.9, 81.5)
V maxS 5125.4 (3035.2, 7936.4) 4488 (3051.8, 7001.3)
CL12S 42.1 (23.0, 68.2) 44.5 (24.5, 73.4)
ωS 0.31 (0.20, 0.51) 0.34 (0.21, 0.53)
σV1S 0.11 (0.03, 0.22) N/A
σV2S 0.20 (0.05, 0.40) N/A
σV maxS 0.15 (0.07, 0.23) N/A
σCL12S 0.20 (0.05, 0.39) N/A
σS0 0.10 (0.03, 0.17) N/A

Model 2* : a Bayesian three-level hierarchical model for the sample mean and variance.

Model 1** : a Bayesian three-level hierarchical model for the sample mean.

90% CI*** : a 90% credit interval. It is represented by its relative scale to the mean.